Square Pharmaceuticals PLC. announcements
313 Dhaka Stock Exchange announcements for Square Pharmaceuticals PLC. (SQURPHARMA) since 2007: results, dividends, board meetings, AGMs, record dates and other price-sensitive information. Showing 2021 (10).
- Resumption after record date
Trading of the shares of the Company will resume on 23.11.2021 after record date.
- Suspension for Record date
Trading of the shares of the Company will remain suspended on record date i.e., 22.11.2021.
- Spot News
Trading of the shares of the Company will be allowed only in the Spot Market and Block transactions will also be settled as per Spot settlement cycle with cum benefit from 18.11.2021 to 21.11.2021. Trading of the shares of the Company will remain suspended on record date i.e., 22.11.2021.
- Q1 Financials
(cont. of SQURPHARMA): The Company has informed that growth in business volume and efficient utilization of working capital along with reduction in tax expense resulted in increased Consolidated Net Operating Cash Flow Per Share. (end)
The first part of this announcement is missing from the archive. - Board Meeting schedule under LR 16(1)
As per Regulation 16(1) of the Dhaka Stock Exchange (Listing) Regulations, 2015, the Company has informed that a meeting of the Board of Directors will be held on November 14, 2021 at 3:00 PM to consider, among others, un-audited financial statements of the Company for the First Quarter (Q1) period ended on September 30, 2021.
- Dividend Declaration and BMRE, Capital Machineries & Land purchase
(Continuation news of SQURPHARMA): The Company has also reported Consolidated EPS of Tk. 17.99, Consolidated NAV per share of Tk. 102.54 and Consolidated NOCFPS of Tk. 12.43 for the year ended on June 30, 2021 as against Tk. 15.07, Tk. 87.28 and Tk. 12.14 respectively for the same period of the previous year. (end)
The first part of this announcement is missing from the archive. - Price Limit Open
There will be no price limit on the trading of the shares of the Company today (24.10.2021) following its corporate declaration.
- Dividend Declaration (Additional Information)
(Continuation news of SQURPHARMA): which allowed us to obtain a healthy 7.63% increment in other income compared to last year's negative growth of 3.80%. Furthermore, the reduced corporate tax rate (22.5% from last year's 25%) for publicly listed entities for the concerned financial year (2020-21) helped us reducing tax expenses which in turn resulted in the increment of EPS. (end)
The first part of this announcement is missing from the archive. - Board Meeting schedule under LR 19(1)
As per Regulation 19(1) of the Dhaka Stock Exchange (Listing) Regulations, 2015, the Company has informed that a meeting of the Board of Directors will be held on October 21, 2021 at 3:00 PM to consider, among others, audited financial statements of the Company for the year ended on June 30, 2021.
- Q3 Financials
(Continuation news of SQURPHARMA): and Consolidated NOCFPS: Consolidated NAV per share is increased due to incremental Net Profit in comparing to the reporting period ended on March 31, 2020. Consolidated EPS increased due to positive revenue. Consolidated NOCFPS decreased due to higher investment on working capital and higher advance tax payment to facilitate revenue growth in comparing to the same reporting period of previous year. (end)
The first part of this announcement is missing from the archive.
Source: Dhaka Stock Exchange announcements. Some posts before 2014 have no title, and 2014–2020 coverage is incomplete.